198 related articles for article (PubMed ID: 28561683)
1. Breast Cancer in the Central Nervous System: Multidisciplinary Considerations and Management.
Lin NU; Gaspar LE; Soffietti R
Am Soc Clin Oncol Educ Book; 2017; 37():45-56. PubMed ID: 28561683
[TBL] [Abstract][Full Text] [Related]
2. Management of Brain and Leptomeningeal Metastases from Breast Cancer.
Pellerino A; Internò V; Mo F; Franchino F; Soffietti R; Rudà R
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33198331
[TBL] [Abstract][Full Text] [Related]
3. Metastasis-acquired changes in clinically actionable genes in triple negative breast cancer patients with central nervous system metastases: Focus on HER2 targeted therapies.
Altundag K
J BUON; 2017; 22(4):1081. PubMed ID: 28952231
[No Abstract] [Full Text] [Related]
4. Luminal subtypes predict improved survival following central nervous system metastasis in patients with surgically managed metastatic breast carcinoma.
Wiens AL; Martin SE; Bertsch EC; Vance GH; Stohler RA; Cheng L; Badve S; Hattab EM
Arch Pathol Lab Med; 2014 Feb; 138(2):175-81. PubMed ID: 24476516
[TBL] [Abstract][Full Text] [Related]
5. Progress in the biological understanding and management of breast cancer-associated central nervous system metastases.
Dawood S; Gonzalez-Angulo AM
Oncologist; 2013 Jun; 18(6):675-84. PubMed ID: 23740934
[TBL] [Abstract][Full Text] [Related]
6. CNS metastases in breast cancer.
Lin NU; Bellon JR; Winer EP
J Clin Oncol; 2004 Sep; 22(17):3608-17. PubMed ID: 15337811
[TBL] [Abstract][Full Text] [Related]
7. Treatment and prognosis of breast cancer patients with brain metastases according to intrinsic subtype.
Kuba S; Ishida M; Nakamura Y; Yamanouchi K; Minami S; Taguchi K; Eguchi S; Ohno S
Jpn J Clin Oncol; 2014 Nov; 44(11):1025-31. PubMed ID: 25156682
[TBL] [Abstract][Full Text] [Related]
8. Metastatic patterns of breast cancer subtypes: what radiologists should know in the era of personalized cancer medicine.
Chikarmane SA; Tirumani SH; Howard SA; Jagannathan JP; DiPiro PJ
Clin Radiol; 2015 Jan; 70(1):1-10. PubMed ID: 25300558
[TBL] [Abstract][Full Text] [Related]
9. Human epidermal growth factor receptor 2-positive breast cancer and central nervous system metastases.
Leyland-Jones B
J Clin Oncol; 2009 Nov; 27(31):5278-86. PubMed ID: 19770385
[TBL] [Abstract][Full Text] [Related]
10. Characteristics and Outcomes of Patients With Breast Cancer With Leptomeningeal Metastasis.
Morikawa A; Jordan L; Rozner R; Patil S; Boire A; Pentsova E; Seidman AD
Clin Breast Cancer; 2017 Feb; 17(1):23-28. PubMed ID: 27569275
[TBL] [Abstract][Full Text] [Related]
11. Leptomeningeal metastases from breast cancer: intrinsic subtypes may affect unique clinical manifestations.
Lee S; Ahn HK; Park YH; Nam DH; Lee JI; Park W; Choi DH; Huh SJ; Park KT; Ahn JS; Im YH
Breast Cancer Res Treat; 2011 Oct; 129(3):809-17. PubMed ID: 21785952
[TBL] [Abstract][Full Text] [Related]
12. Metastatic breast carcinoma in pleural fluid: Correlation of receptor and HER2 status with the primary carcinoma-a pilot study.
Francis IM; Alath P; George SS; Jaragh M; Al Jassar A; Kapila K
Diagn Cytopathol; 2016 Dec; 44(12):980-986. PubMed ID: 27666130
[TBL] [Abstract][Full Text] [Related]
13. Central nervous system metastases in patients with HER2-positive metastatic breast cancer: incidence, treatment, and survival in patients from registHER.
Brufsky AM; Mayer M; Rugo HS; Kaufman PA; Tan-Chiu E; Tripathy D; Tudor IC; Wang LI; Brammer MG; Shing M; Yood MU; Yardley DA
Clin Cancer Res; 2011 Jul; 17(14):4834-43. PubMed ID: 21768129
[TBL] [Abstract][Full Text] [Related]
14. Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma.
Bendell JC; Domchek SM; Burstein HJ; Harris L; Younger J; Kuter I; Bunnell C; Rue M; Gelman R; Winer E
Cancer; 2003 Jun; 97(12):2972-7. PubMed ID: 12784331
[TBL] [Abstract][Full Text] [Related]
15. Advances in the Management of Central Nervous System Metastases from Breast Cancer.
Avila J; Leone JP
Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293379
[TBL] [Abstract][Full Text] [Related]
16. Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer.
Bae SY; Kim S; Lee JH; Lee HC; Lee SK; Kil WH; Kim SW; Lee JE; Nam SJ
BMC Cancer; 2015 Mar; 15():138. PubMed ID: 25880075
[TBL] [Abstract][Full Text] [Related]
17. Survival of breast cancer patients with synchronous or metachronous central nervous system metastases.
Ho VK; Gijtenbeek JM; Brandsma D; Beerepoot LV; Sonke GS; van der Heiden-van der Loo M
Eur J Cancer; 2015 Nov; 51(17):2508-16. PubMed ID: 26277099
[TBL] [Abstract][Full Text] [Related]
18. CNS complications of breast cancer: current and emerging treatment options.
Kaal EC; Vecht CJ
CNS Drugs; 2007; 21(7):559-79. PubMed ID: 17579499
[TBL] [Abstract][Full Text] [Related]
19. Molecular subtypes as a predictor of response to neoadjuvant chemotherapy in breast cancer patients.
Subbiah S; Gopu G; Senthilkumar P; Muniasamy P
Indian J Cancer; 2017; 54(4):652-657. PubMed ID: 30082552
[TBL] [Abstract][Full Text] [Related]
20. Age related influence of triple receptor status on metastatic breast cancer post relapse survival.
Todorovic-Rakovic N; Neskovic-Konstantinovic Z
J BUON; 2013; 18(4):851-8. PubMed ID: 24344008
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
